Evidence map›Paper›PMID 36176411›Full record

ArticleFrontiers in oncology2022

Endocrine therapy for metastatic solid pseudopapillary neoplasm of the pancreas: A case report.

Anna Kornietskaya, Sevindzh Evdokimova, Andrei Kachmazov, Alexander Fedenko, Larisa Bolotina, Dmitriy Sidorov, Nadezhda Volchenko, Natalia Goeva, Anastasia Govaleshko, Andrey Kaprin

Registry-linked trialOpen access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06914674 (Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06914674 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas

TypeinterventionalSponsorFudan UniversityRan2025 to 2028Enrolled30ConditionsPancreatic NeoplasmsArmsTamoxifen 20 mg
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Anna KornietskayaP. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, Russia.
Sevindzh EvdokimovaP. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, Russia.
Andrei KachmazovP. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, Russia.
Alexander FedenkoP. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, Russia.
Larisa BolotinaP. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, Russia.
Dmitriy SidorovCity Clinical Oncological Hospital No1, Moscow, Russia.
Nadezhda VolchenkoP. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, Russia.
Natalia GoevaP. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, Russia.
Anastasia GovaleshkoP. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, Russia.
Andrey KaprinP. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, Russia.
Ministry of Health of the Russian Federation · RUP.A. Hertzen Moscow Oncology Research Institute · RUMoscow City Oncology Hospital №62 · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Solid pseudopapillary neoplasm (SPN) of the pancreas is an extremely rare tumor, associated with favorable prognosis and long-term survival in patients with advanced disease. However, limited data exist on systemic therapy for such patients. Herein, we present a case of a young woman with a history of SPN, who progressed after multiple surgical resections and chemotherapy regimens. The immunohistochemistry (IHC) showed overexpression of estrogen receptors (ER) and progesterone receptors (PR) in tumor tissue. The patient started to receive tamoxifen and showed a durable response to endocrine therapy.

Indexed as

case reportendocrine therapypancreassolid pseudopapillary neoplasm (SPN)tamoxifen

Identifiers

PMID36176411
PMCPMC9514425
OpenAlexW4295846740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.